Page last updated: 2024-10-30

lansoprazole and ER-Negative PR-Negative HER2-Negative Breast Cancer

lansoprazole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Beebe, J1
Josephraj, S1
Wang, CJ1
Danielson, J1
Cui, Q1
Huang, C1
Barlow, L1
Zhang, RH1
Zhang, T1
Nakshatri, H1
Dong, Z1
Li, X1
Liu, JY1
Zhang, JT1

Other Studies

1 other study available for lansoprazole and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.
    Journal of medicinal chemistry, 2022, 10-27, Volume: 65, Issue:20

    Topics: Fatty Acid Synthases; Humans; Lansoprazole; Lipids; Oxidoreductases; Proton Pump Inhibitors; Sulfide

2022